Compendium

Walkthrough: Design an FDA Drug Approval Pipeline (Pre-IND through BLA/NDA)

20 min read

Walkthrough: Design an FDA Drug Approval Pipeline (Pre-IND through BLA/NDA)

This walkthrough scopes the full development pipeline for an investigational therapeutic — small molecule, biologic, or peptide — from discovery candidate selection through US FDA approval and parallel EMA + PMDA registration. The target asset is a hypothetical first-in-class oral GLP-1/GIP receptor co-agonist for obesity + Type 2 diabetes, with a contingent oncology cachexia indication; this format covers both metabolic-drug and biologic dynamics. Total program cost $1-2B including failed-shot allocation; timeline 8-12 years from IND to approval for typical candidates; phase-success-weighted probability of approval from Phase 1 entry is ~10-13% (BIO/Informa Pharma Intelligence “Clinical Development Success Rates 2011-2020” data, updated through 2024).

Reference programs: Novo Nordisk semaglutide (Ozempic + Wegovy + Rybelsus), Eli Lilly tirzepatide (Mounjaro + Zepbound), Merck Keytruda (pembrolizumab), Biogen Aduhelm (aducanumab — accelerated 2021, voluntarily withdrawn 2024), Biogen/Eisai Leqembi (lecanemab), Pfizer Paxlovid (nirmatrelvir/ritonavir EUA), Vertex Casgevy (exa-cel, sickle cell gene therapy FDA Dec 2023), Sarepta Elevidys (delandistrogene moxeparvovec, DMD gene therapy), Lilly donanemab (Kisunla, Alzheimer’s), Novo CagriSema (Phase 3 setback Dec 2024), Lilly retatrutide (Phase 3 obesity).

1. Program spec

ParameterTargetNotes
Indication (primary)Type 2 diabetes (T2D) + obesity (chronic weight management)$40-80B addressable by 2030
ModalityOral peptide (lipid conjugate + permeation enhancer)Compares vs injectable GLP-1 standard of care
Phase entryPre-IND end-2025First-in-human Phase 1 mid-2026
Target NDA filingQ2 2032Standard review or breakthrough/accel
Approval targetH1 203310-month standard review
Patient exposure pre-approval~5,500 patients (Phase 1-3)ICH E1 guideline (1,500 6-mo + 300-600 12-mo)
Total program cost$1.2-1.9BIncluding 60-70% attrition allocation
Phase 3 trial size4,500-7,500 patients across 2-3 trialsComparator vs placebo + semaglutide
Manufacturing scale-upPhase 2 end → 3-15 tonnes API/yr at NDAPeptide synthesis + RP-HPLC purification

2. Discovery to development candidate (Pre-IND)

2.1 Lead optimization

Discovery work — out of scope here, but assume 4-6 years from target validation through IND-enabling. Lead optimization for a GLP-1 co-agonist involves:

  • High-throughput screening of peptide libraries (>10,000 analogs) against cloned hGLP-1R + hGIPR overexpressed in CHO-K1 or HEK293 cells.
  • cAMP accumulation assay (HTRF, Cisbio/PerkinElmer) for receptor activation; β-arrestin recruitment (DiscoverX PathHunter).
  • Pharmacokinetic optimization for oral bioavailability: lipid acylation (C18 fatty acid like semaglutide’s spacer-linked C18 diacid), N-methylation to resist proteolysis, conformational constraint.
  • Permeation enhancer selection: SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate, Rybelsus precedent) or C10 (sodium caprate).

Development candidate selection: typically 3-5 short-listed leads, finalized at a “decision-tree” meeting incorporating PK/PD, safety, manufacturability, IP position, freedom-to-operate.

See structural-biology and medicinal-and-photo-chemistry.

2.2 IND-enabling activities

A coordinated 12-18 month program executes:

  1. Manufacturing — GMP API at 0.5-5 kg for tox + clinical Phase 1. Solid-phase peptide synthesis (SPPS) on a Wang or 2-chlorotrityl resin (CEM Liberty Blue, Biotage SP Wave, Protein Technologies Symphony X). Coupling agents: HATU/DIC/Oxyma. Purification: preparative RP-HPLC on C8 or C18 (Waters Prep 150, Gilson PLC 2050) with TFA/water/acetonitrile gradient, ≥98% purity. Lyophilization for storage.
    • CDMO options: Bachem (Bubendorf CH + Vista CA), CordenPharma (Boulder CO + Frankfurt DE), Polypeptide Group (Strasbourg FR + Torrance CA), PolyPeptide Laboratories, Lonza (Visp CH solid-state peptide line), CSBio.
  2. Formulation — oral tablet with permeation enhancer + API + standard excipients (microcrystalline cellulose, mannitol, magnesium stearate). Tablet compression on Korsch XL400 or Fette FE55 rotary press. Coating with Opadry for taste-masking.
  3. GLP toxicology — 28-day + 90-day repeat-dose toxicity in rat + non-rodent (cynomolgus macaque or dog), per ICH M3(R2). For peptides with cross-reactive receptors in primates, monkey is mandatory. CROs: Charles River Laboratories (Reno NV, Edinburgh UK, Senneville QC), Labcorp Drug Development (Madison WI, Greenfield IN, Eye UK), Inotiv (Mt Vernon IN — acquired Envigo 2021), Crown Bioscience (Taicang CN + San Diego CA).
  4. GLP safety pharmacology — ICH S7A core battery: cardiovascular (telemetered dog), respiratory (rat plethysmograph), CNS (Irwin/FOB rat). hERG patch-clamp (HEK293-hERG; Charles River Cleveland Cleveland Clinic Lerner Research; Chantest/Cyprotex now Labcorp) for QT-prolongation risk per ICH S7B.
  5. Genotoxicity — Ames bacterial mutagenicity (ICH S2(R1)), in vitro mouse lymphoma or chromosome aberration, in vivo micronucleus.
  6. Reproductive toxicity — segment I (fertility), II (embryo-fetal development), III (pre/post-natal) per ICH S5(R3) — Phase 2/3 enabling, but planning starts at IND.
  7. Carcinogenicity — 2-year rodent + Tg.rasH2 6-month transgenic mouse, per ICH S1; required for >6-month patient exposure, conducted Phase 2/3.
  8. CMC (Chemistry, Manufacturing, Controls) — drug substance + drug product specifications, stability program initiated (ICH Q1A(R2)), reference standards, impurity profile.

Pre-IND meeting with FDA Division of Diabetes, Lipid Disorders, and Obesity (DDLDO), Office of Cardiology, Hematology, Endocrinology, and Nephrology: optional but highly recommended; sets clarity on Phase 1 study design + comparator + safety database expectations. Free, ~60-90 day lead time.

3. IND submission

3.1 IND package structure

The IND (Investigational New Drug application, 21 CFR 312) is a multi-volume eCTD (electronic Common Technical Document, ICH M2/M4) submission organized into 5 modules:

  • Module 1 — administrative (Form FDA 1571, cover letter, US agent, financial disclosure)
  • Module 2 — quality + nonclinical + clinical overviews and summaries (the “Module 2.5 / 2.6 / 2.7” QOS, NOC, CSR summaries)
  • Module 3 — CMC (quality)
  • Module 4 — nonclinical study reports (tox, PK, safety pharmacology)
  • Module 5 — clinical study reports (none yet at IND; investigator brochure replaces)

Plus the Investigator’s Brochure (IB) — comprehensive document for clinical investigators.

eCTD publishing tools: Lorenz docuBridge, Veeva Vault RIM/Submissions, Extedo eCTDmanager, Calyx (formerly Parexel) Submissions Workbench. Cost $80K-300K/yr for the platform + publishing team.

3.2 FDA review

  • 30-day safety review — FDA reviews IND; absent clinical hold, sponsor may proceed Day 31.
  • Clinical hold — FDA may impose if safety, study design, or IB inadequate; partial hold (specific dose, population, or duration) or full hold. Common reasons: insufficient nonclinical safety, inadequate informed consent, vulnerable population concerns.
  • Type B pre-IND / End-of-Phase 1 / End-of-Phase 2 meetings — formal opportunities to align with FDA; minutes are binding.

4. Phase 1 — first-in-human

4.1 Study design

  • SAD (Single Ascending Dose) — 6-8 dose cohorts of 8 healthy volunteers each (6 active + 2 placebo); intensive PK sampling; safety monitoring committee (SMC) decision between cohorts.
  • MAD (Multiple Ascending Dose) — 4-6 dose cohorts of 12 each over 28 days; demonstrates steady-state PK, multi-dose safety, preliminary PD.
  • Food effect, DDI (drug-drug interaction) sub-studies — typically Phase 1 or transition to Phase 2.

Total Phase 1 enrollment: ~80-150 subjects. Duration ~12-18 months.

4.2 Sites and conduct

  • Phase 1 units: Celerion (Lincoln NE), Quotient Sciences (Nottingham UK + Miami FL), ICON Early Phase (Allentown PA), Parexel (Glendale CA + Berlin DE), Hammersmith Medicines Research (London UK), CMAX (Adelaide AU), PRA Health Sciences (now part of ICON).
  • ~50% of US Phase 1 capacity now offshored to Singapore, Australia, UK (faster ethics + lower cost).
  • IRB / IEC review per 21 CFR 56 / ICH E6(R3) good clinical practice. WCG (Western IRB / Copernicus Group / Schulman), Advarra, Salus IRB are dominant central IRBs.

4.3 Bioanalytical

LC-MS/MS validated per FDA Bioanalytical Method Validation Guidance (May 2018) for plasma concentrations: Waters Acquity / Thermo Vanquish + Sciex 6500+ or Thermo Altis. Sensitivity 0.05-1.0 ng/mL typical for peptides; LC method 5-15 min run; ISTD (stable-isotope-labeled internal standard) mandatory.

CRO bioanalytical: PPD/Thermo Laboratory Services, Charles River, Frontage Labs, Q² Solutions (acquired by IQVIA 2017), Eurofins BioPharma Product Testing.

4.4 Phase 1 success criteria

  • No DLTs (dose-limiting toxicities) up to anticipated therapeutic exposure + safety margin
  • PK confirms predicted human exposure within 0.5-2× IVIVC (in vitro to in vivo correlation)
  • Preliminary PD signal (HbA1c reduction, weight loss, biomarker shift) supportive

Phase 1 success rate per Informa Pharma Intelligence 2011-2020 = ~52% for endocrine/metabolic.

5. Phase 2 — proof of concept and dose-finding

5.1 Study design (Phase 2a + 2b)

  • Phase 2a (POC, proof of concept) — 50-150 patients with the disease, 8-12 weeks treatment, randomized vs placebo, primary endpoint biomarker-based (HbA1c change from baseline at 12 weeks).
  • Phase 2b (dose-finding) — 200-600 patients, 4-6 dose arms + placebo, 24-26 weeks. Endpoint HbA1c + body weight % change. Determines Phase 3 doses.

Adaptive designs increasingly favored: response-adaptive randomization, group-sequential interim analyses (for safety + futility), Bayesian dose-response modeling (MCP-Mod, Emax, Bayesian Optimal Interval BOIN for oncology). Statistical software: SAS, R (DoseFinding, BOIN packages), East (Cytel), FACTS (Berry Consultants), nQuery, Phoenix WinNonlin for PK/PD.

5.2 Sites + investigators

300-800 patients across 30-80 sites in 3-6 countries. Site selection criteria:

  • Track record + GCP audit history
  • Patient population access (T2D — endocrinology + primary care + academic medical centers)
  • Country regulatory speed (Australia, US, UK, Germany fastest; India + LatAm cheaper but slower contract execution)

CROs (full-service): IQVIA (largest), ICON, Parexel, PPD/Thermo, Syneos Health (merger of INC Research + inVentiv 2018, then went private 2024), Labcorp Drug Development, Medpace, Worldwide Clinical Trials.

5.3 EDC + clinical data

  • EDC (Electronic Data Capture): Medidata Rave (Dassault Systèmes), Veeva CDMS, Oracle Clinical One, Castor EDC, OpenClinica.
  • ePRO / eCOA (patient-reported outcomes): Medable, Signant Health (formerly Bracket + CRF Health), Clario (Clinical Ink + Bioclinica + others), THREAD.
  • IRT (Interactive Response Technology) for randomization + drug supply: Almac IRT, Calyx IRT, Bracket IRT (now Signant).
  • CTMS (Clinical Trial Management System): Veeva CTMS, Medidata CTMS, Oracle Siebel CTMS.
  • Safety database (pharmacovigilance): Oracle Argus, Veeva Vault Safety, ArisGlobal LifeSphere, Ennov Safety.

5.4 End-of-Phase 2 meeting

Critical alignment milestone with FDA: Phase 3 design, primary endpoint, statistical plan, dose selection, comparator, safety database adequacy, special populations. Sponsor submits briefing book 30 days ahead; FDA written responses + face-to-face/Zoom meeting; minutes binding for 18-24 months.

Phase 2 success rate ~28% per BIO/Informa; metabolic/endocrine ~32%.

6. Phase 3 — confirmatory

6.1 Trial design

For T2D + obesity dual indication, the registration package typically requires 2-3 pivotal Phase 3 trials:

TrialNDurationComparatorPrimary endpoint
T2D monotherapy700-1,20052 wkPlacebo + Metformin standardHbA1c change at 26 wk
T2D add-on1,200-2,00052 wkSemaglutide 1 mg SCHbA1c at 26 wk; weight at 52 wk
Obesity (no T2D)2,500-4,00068 wkPlaceboBody weight % change at 68 wk
Cardiovascular outcomes (CVOT)6,000-12,0003-5 yrPlaceboMACE (3-point composite)

Total Phase 3 enrollment: 10,000-19,000 patients across the program if CVOT is concurrent. CVOT is required for T2D approval per FDA 2008 guidance (Bydureon-era) but the 2020 update softened to “demonstrate not unacceptable CV risk” — many sponsors now run CVOT as a post-approval commitment.

6.2 Biostatistics framework

Statistical methods (per ICH E9 + E9(R1) on estimands):

  • Estimand framework — defines treatment effect under specified handling of intercurrent events (treatment discontinuation, rescue meds, COVID disruption). E9(R1) (2019 finalization) requires every primary endpoint to be described as an estimand.
  • MMRM (mixed-effects model for repeated measures) — standard for change-from-baseline endpoints with missing data.
  • Multiple imputation + tipping-point — sensitivity analyses for missing data.
  • Hierarchical testing — control alpha across multiple endpoints (HbA1c, weight, BP, lipids).
  • Group-sequential designs with O’Brien-Fleming or Lan-DeMets alpha-spending for interim efficacy + futility.
  • Bayesian methods — increasingly accepted (FDA Bayesian guidance 2010; Complex Innovative Trial Design pilot program 2018-2023; CID PoC pathway 2024).

CROs / biostatistics specialists: Berry Consultants (Bayesian + adaptive design), Cytel (East software + adaptive design), Phastar, ICON Statistical Services.

6.3 Phase 3 execution + cost

  • Site count: 200-500 globally per trial.
  • Per-patient cost: 150K+).
  • Total Phase 3 budget for the program: $700M-1.2B over 3-4 years.
  • CRO contract: typically $200M-500M for the full Phase 3 program.

Phase 3 success rate ~58% per BIO/Informa; metabolic ~60%.

7. FDA expedited programs

7.1 Designations

DesignationThresholdBenefit
Fast TrackSerious condition + nonclinical/clinical dataRolling review, frequent FDA interaction
Breakthrough TherapySerious condition + preliminary clinical evidence of substantial improvement on a clinically significant endpointIntensive FDA guidance, rolling review, senior FDA staff involvement
Accelerated ApprovalSurrogate endpoint reasonably likely to predict clinical benefitApproval on surrogate; post-marketing confirmatory trial required (PMR)
Priority ReviewSignificant improvements in safety/effectiveness6-month standard NDA review vs 10-month

A T2D/obesity oral GLP-1 typically does not qualify for breakthrough/fast track (existing options exist), but could attract Priority Review for novel mechanism. Oncology cachexia sub-indication could attract Breakthrough or Orphan Drug if patient population <200K US.

7.2 Orphan Drug

  • Per Orphan Drug Act 1983: <200,000 US patients OR no reasonable expectation of recouping costs.
  • Benefits: 7-yr market exclusivity (post-approval), tax credits (25% qualified clinical expense, post-IRA reduction), PDUFA fee waiver.
  • 50%+ of new molecular entities in 2020-2024 had orphan designation for at least one indication.

7.3 Real World Evidence (RWE)

FDA increasingly accepts RWE under 21st Century Cures Act + PDUFA VII commitments: registry data, claims (Medicare, Optum, Flatiron), EHR-derived endpoints. For supplemental indications + post-marketing safety, RWE is now routine; for primary approval, used selectively.

8. NDA / BLA submission

8.1 Package

  • NDA (New Drug Application, small molecule + peptide) per 21 CFR 314.
  • BLA (Biologics License Application) per 21 CFR 600 — for biologics, monoclonal antibodies, vaccines, gene therapies.

Our oral peptide goes via NDA 505(b)(1) (full application).

Submission again in eCTD format. Typical NDA: 100K-500K pages across all modules. Module 5 contains every clinical study report (CSR per ICH E3); each pivotal CSR is itself ~5,000-15,000 pages including appendices.

8.2 PDUFA fees (FY 2026, in effect Oct 1 2025 - Sep 30 2026)

  • Application fee (clinical data): $4,310,002
  • Application fee (no clinical data): $2,155,001
  • Program fee (per prescription drug program, annual): $416,734

Source: FDA PDUFA VII Fee Schedule (Federal Register Sep 2024 / Aug 2025 update). Numbers move ~3-7% annually with PDUFA reauthorization adjustments.

Orphan Drug + small business (<500 employees, first application): fee waivers possible.

8.3 Review

  • Filing review — 60 days; FDA accepts or refuses to file (RTF).
  • Standard review clock — 10 months from filing acceptance (~12 months from submission); Priority Review 6 months.
  • Advisory committee — convenes for novel mechanisms, contested safety, or high-profile programs. Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) reviewed semaglutide, tirzepatide, donanemab.
  • Mid-cycle communication — 5 months in; FDA shares preliminary findings.
  • Late-cycle communication — 3 months pre-PDUFA date; final issues raised.
  • Inspections — Pre-Approval Inspection (PAI) of API + DP manufacturing; clinical site BIMO inspection; bioanalytical lab inspection. Form 483 observations during PAI are the biggest delay risk.

8.4 Approval outcomes

  • Approval letter — drug approved; labeling negotiated separately; REMS if required.
  • Complete Response Letter (CRL) — deficiencies identified; sponsor must address and resubmit. Resubmission classified Class 1 (2 mo) or Class 2 (6 mo) review.
  • Withdrawal — sponsor pulls back voluntarily.

CRL rate for new NDAs ~25-30% per FDA data 2018-2024.

9. Parallel paths: EMA + PMDA

9.1 EMA (Europe)

  • MAA (Marketing Authorisation Application) centralized procedure for new active substances. Submitted to EMA, reviewed by CHMP (Committee for Medicinal Products for Human Use).
  • Timeline: 210 days (active review) + clock stops; typical 12-18 months elapsed.
  • Fees: ~€326,500 for full MAA + per-indication and post-authorization fees (2025).
  • Subsequent EU approval applies across all 30 EEA member states.
  • Different reference labels (SmPC summary of product characteristics) vs FDA Prescribing Information; EU PV (pharmacovigilance) via EudraVigilance.

9.2 PMDA (Japan)

  • J-NDA under PMDA review.
  • Japanese clinical data typically required (or bridging study justified by ethnic sensitivity analysis per ICH E5). For metabolic drugs, ~20-30% of Phase 3 enrollment from Japan satisfies most reviewers.
  • Sakigake (priority) designation analogous to FDA Breakthrough.
  • Approval timeline 12-18 months.

9.3 ICH harmonization

  • ICH M4 (CTD format), M2 (eCTD), E2 (PV), E3 (CSR), E6(R3) (GCP), E9(R1) (estimands), E14 (QT), M3(R2) (nonclin), Q1-Q12 (CMC) all harmonized across FDA + EMA + PMDA + Health Canada + TGA + ANVISA + China NMPA (since 2017).
  • Same Phase 3 dataset typically supports global filings with minor regional adaptations (Japanese sub-study, EU-specific safety reporting, China bridging).

10. Post-approval — REMS, PV, lifecycle

10.1 REMS (Risk Evaluation and Mitigation Strategies)

FDA-required when serious risks need active management. Components:

  • Medication Guide (FDA-approved patient info)
  • Communication Plan (HCP letters)
  • Elements to Assure Safe Use (ETASU) — prescriber certification, patient enrollment, lab monitoring, restricted distribution
  • Implementation system + assessment

GLP-1 drugs to date have not had REMS. Drugs requiring REMS: Accutane (iPLEDGE), Mifepristone, thalidomide (S.T.E.P.S.), clozapine, opioids (REMS-O), Tysabri (TOUCH), CAR-T cells (each has individual REMS).

10.2 Pharmacovigilance

  • 21 CFR 314.80 / 600.80 mandates AE (adverse event) reporting: 15-day expedited for serious + unexpected; periodic safety update reports (PSUR / PBRER) every 6-12 months.
  • FAERS (FDA Adverse Event Reporting System) is the public-facing US PV database; EudraVigilance EU equivalent.
  • Sponsor maintains internal safety database (Argus, Vault Safety) processing 10K-100K cases/yr for a marketed drug.
  • Sentinel Initiative — FDA’s distributed RWE PV platform spanning Medicare, Optum, commercial claims, EHR data; queries safety signals across 300M+ patient lives.

10.3 Lifecycle management

  • Manufacturing changes per ICH Q12: Established Conditions, PACMP (Post-Approval Change Management Protocol).
  • New indications + new formulations + new strengths via NDA supplements (sNDA) or PAS (Prior Approval Supplement).
  • Patent protection: composition of matter + method of use + formulation patents typically span 20 years from filing, plus Hatch-Waxman extension up to 5 yr for FDA review delay (max 14 yr post-approval). See intellectual-property-deep.
  • Data exclusivity: 5 yr NCE (new chemical entity), 12 yr BLA, 7 yr orphan, 6 mo pediatric extension.

11. Cost build-up

11.1 Single-program cost (no attrition allocation)

PhaseCost rangeDuration
Discovery + lead optimization$50-200M3-5 yr
IND-enabling (CMC, tox, safety pharm, formulation)$20-80M12-18 mo
Phase 1 (SAD/MAD, food effect, DDI)$15-40M12-18 mo
Phase 2 (a + b)$50-150M24-36 mo
Phase 3 (3 pivotal trials + CVOT)$700M-1,200M36-48 mo
NDA preparation + submission$30-80M12 mo
Manufacturing scale-up (Phase 2 → commercial)$50-300M24-36 mo overlap
Total program (one molecule, no failures)$0.9-2.0B8-12 yr

11.2 Attrition-weighted “shots on goal” cost

DiMasi-Grabowski-Hansen 2016 (Journal of Health Economics): capitalized R&D cost per approved drug 3.7-4.5B inflation-adjusted to 2026. Tufts Center for the Study of Drug Development updates put 2024 figure at 4.0-5.5B including 8-10% cost of capital. The variance reflects:

  • Therapeutic area (oncology: ~3-4B; antibiotic / antiviral: ~$2-3B)
  • Modality (small molecule: 3-5B; cell/gene therapy: $4-6B)
  • Failure attribution (the cost of all preclinical leads that never reached IND)

For a single molecule progressing without setbacks: 2.5-5.5B.

11.3 Real-world reference programs (publicly disclosed estimates)

  • Novo Nordisk semaglutide (Ozempic + Wegovy + Rybelsus) total cumulative R&D + manufacturing build-up through 2024: ~$10-15B (multi-indication, multi-formulation)
  • Lilly tirzepatide (Mounjaro + Zepbound): ~$8-12B through 2024
  • Merck Keytruda: ~10-15B R&D over the full lifecycle (now 25B+ in annual sales as of 2024)
  • Biogen Aduhelm: ~$1B Phase 3 + CMS coverage decision wiped most commercial value, withdrawal 2024
  • Biogen/Eisai Leqembi: ~$1.2-1.5B development cost; commercial uptake gated on CMS reimbursement
  • Sarepta Elevidys (DMD gene therapy, accelerated approval 2023 + traditional 2024): ~3.2M list price per dose
  • Vertex Casgevy: ~$1.5B development for the platform + indication

12. Manufacturing readiness

12.1 Scale-up curve

StageAPI quantityModeSite
IND / Phase 10.5-5 kgSPPS, batchCDMO pilot
Phase 220-200 kgSPPS or hybrid SPPS + ligationCDMO clinical scale
Phase 31-5 tMulti-vessel SPPS or convergent + ligationCDMO commercial scale or sponsor-owned
Launch5-15 t/yrSame; multi-site for redundancyCommercial network
Steady state (3-5 yr post launch)30-100 t/yrProcess intensificationOften >2 sites

Peptide-API CDMOs at commercial scale: Bachem (largest, ~$0.7B revenue 2024), CordenPharma, PolyPeptide Group, Lonza (Visp solid-state line), CSBio, Almac, Piramal. The GLP-1 boom of 2022-2025 stretched peptide CDMO capacity globally — see design-pharma-fill-finish-line for fill-finish bottleneck.

12.2 Process validation

Per ICH Q8/Q9/Q10/Q11/Q12 and FDA Process Validation Guidance 2011:

  • Stage 1 — Process Design — process characterization, design space (Quality by Design).
  • Stage 2 — Process Qualification (PQ) — 3 validation batches at commercial scale at the commercial site. Performed pre-NDA submission.
  • Stage 3 — Continued Process Verification (CPV) — ongoing CPP/CQA monitoring + APR (annual product review).

12.3 Drug product

  • Tablet manufacturing: granulation (wet or dry), blending (Bohle or GEA Buck), compression (Korsch or Fette), coating (O’Hara Lab Coater).
  • For SNAC-enhanced oral peptide tablets, the permeation-enhancer-peptide co-formulation is the critical patent + know-how layer; Rybelsus references this in its FDA label.
  • Packaging: HDPE bottles + child-resistant caps, or blister cards (PVC/PVDC, cold-form Alu/Alu).
  • Stability program per ICH Q1A(R2) — 25°C/60% RH, 30°C/65% RH, 40°C/75% RH at multiple pull points 0/3/6/9/12/18/24/36 months.

13. IP and commercial readiness

  • Composition of matter patent filed at lead optimization; 20-yr term + Hatch-Waxman PTE.
  • Method of use patents for specific indications.
  • Formulation patents for the permeation enhancer + tablet structure.
  • Process patents for the synthesis.
  • PCT filing → national phase in US + EP + JP + CN + IN + BR + KR + MX + AU + CA + and ~30 others.
  • Freedom-to-operate (FTO) analysis at every stage; Novo + Lilly hold extensive peptide IP from semaglutide + tirzepatide eras — landmark Novo v. Lilly tirzepatide patent litigation (PTAB IPR2023-00770) shapes design-around space.

Commercial readiness in parallel with NDA filing:

  • Reimbursement strategy: FDA approval ≠ payer coverage. CMS (Medicare Part D), commercial payer PBMs (CVS Caremark, Express Scripts, OptumRx), state Medicaid each negotiated separately.
  • Inflation Reduction Act (2022) Medicare drug-price negotiation — applies after 9-13 yr post-launch (small molecule / biologic). Negotiated price ceilings for top-selling drugs starting 2026 (semaglutide list, 2027 effective).
  • Manufacturing redundancy + tier-1 commercial supply contracts (Catalent + Lonza + Patheon + Almac fill-finish).
  • Launch sequencing: US first (largest market, GxP-mature), then EU launches in waves driven by EU country pricing-and-reimbursement (NICE in UK, G-BA in DE, HAS in FR, TLV in SE).

14. Recent landmark approvals (reference cases)

  • Mounjaro (tirzepatide) — Lilly, FDA approved May 2022 (T2D), Nov 2023 obesity branded as Zepbound. ~$50B revenue trajectory 2024 → 2030 projected.
  • Wegovy (semaglutide 2.4 mg SC weekly, obesity) — Novo, FDA approved Jun 2021.
  • Rybelsus (oral semaglutide 7/14 mg) — Novo, FDA approved Sep 2019; established the oral-peptide-with-SNAC pathway.
  • Leqembi (lecanemab) — Biogen/Eisai, accelerated Jan 2023, full approval Jul 2023 (Alzheimer’s). Reference for amyloid mAb space alongside withdrawn Aduhelm and approved Kisunla (donanemab, Lilly Jul 2024).
  • Casgevy (exa-cel) — Vertex/CRISPR Therapeutics, FDA Dec 2023, first CRISPR gene-editing therapy (sickle cell + β-thalassemia). $2.2M list price.
  • Elevidys (delandistrogene moxeparvovec) — Sarepta, accelerated Jun 2023, traditional Jun 2024 (Duchenne MD). $3.2M list price.
  • Paxlovid (nirmatrelvir/ritonavir) — Pfizer, EUA Dec 2021, NDA approval May 2023 (COVID-19).
  • Veozah (fezolinetant) — Astellas, FDA May 2023 (menopausal vasomotor symptoms — first non-hormonal NK3-antagonist).
  • Voquezna (vonoprazan) — Phathom, FDA Nov 2023 (potassium-competitive acid blocker).

15. Risk register

  • Phase 3 failure — 40-45% of programs reaching Phase 3 fail; modal cause is efficacy (insufficient effect size vs comparator, missed primary endpoint).
  • Safety signal in long-term exposure — particularly cardiovascular, hepatic, oncological. Aduhelm + ARIA-E / -H amyloid mAb risk; tirzepatide + MTC label warning; phen-fen (1997 withdrawal); Vioxx (2004); Avandia (CV risk + restrictions).
  • CMC delays at PAI — Form 483 observations at PAI delay approval 3-12 mo. Mitigation: 2-3 dry-run inspections by external consultants pre-PAI.
  • CRL — 25-30% NDAs receive CRL; typical resubmission adds 6-18 mo.
  • REMS imposition late — adds complexity to launch + sales force training.
  • Patent litigation — generic ANDA challenges + biosimilar BPCIA litigation start as early as 4 yr pre-LOE; orange-book listing strategy + secondary patents (formulation, method-of-use) extend exclusivity.
  • Pricing pressure — IRA negotiation, ICER reports, state PDAB (Prescription Drug Affordability Boards in CO, MD, OR, WA, NH, MN since 2019-2024) increasingly constrain US pricing.
  • Manufacturing single-source failure — Novo’s Catalent acquisition (Feb 2024 $16.5B by Novo Holdings) was driven by precisely this concern for semaglutide supply.
  • Geopolitical — BIOSECURE Act (US 2024-2025) restricts certain China-based CDMO contracts (WuXi AppTec + WuXi Biologics named); sponsors with Chinese supply must dual-source.

16. Adjacent

Graph View

Backlinks